Teacher Retirement System of Texas Sells 3,431 Shares of Aerie Pharmaceuticals Inc (AERI)

Teacher Retirement System of Texas cut its holdings in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 33.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,903 shares of the company’s stock after selling 3,431 shares during the period. Teacher Retirement System of Texas’ holdings in Aerie Pharmaceuticals were worth $374,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Neuberger Berman Group LLC lifted its stake in Aerie Pharmaceuticals by 22.6% during the first quarter. Neuberger Berman Group LLC now owns 320,500 shares of the company’s stock valued at $17,387,000 after purchasing an additional 59,000 shares during the last quarter. Thrivent Financial for Lutherans lifted its stake in Aerie Pharmaceuticals by 1.3% during the first quarter. Thrivent Financial for Lutherans now owns 108,311 shares of the company’s stock valued at $5,876,000 after purchasing an additional 1,411 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in Aerie Pharmaceuticals by 10.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 182,345 shares of the company’s stock valued at $9,893,000 after purchasing an additional 17,740 shares during the last quarter. Swiss National Bank raised its holdings in shares of Aerie Pharmaceuticals by 2.5% during the first quarter. Swiss National Bank now owns 53,900 shares of the company’s stock valued at $2,924,000 after acquiring an additional 1,300 shares during the period. Finally, Prudential Financial Inc. raised its holdings in shares of Aerie Pharmaceuticals by 9.2% during the first quarter. Prudential Financial Inc. now owns 57,910 shares of the company’s stock valued at $3,142,000 after acquiring an additional 4,890 shares during the period.

AERI has been the topic of a number of recent analyst reports. Canaccord Genuity set a $86.00 price target on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, May 15th. Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, April 17th. Seaport Global Securities restated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Monday, March 5th. BidaskClub upgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 6th. Finally, HC Wainwright set a $78.00 price target on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, March 1st. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Aerie Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $76.50.



Aerie Pharmaceuticals stock opened at $64.15 on Friday. The company has a current ratio of 13.57, a quick ratio of 13.53 and a debt-to-equity ratio of 0.52. Aerie Pharmaceuticals Inc has a twelve month low of $47.05 and a twelve month high of $66.60.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings data on Tuesday, May 8th. The company reported ($0.83) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.04. equities analysts anticipate that Aerie Pharmaceuticals Inc will post -3.75 earnings per share for the current year.

In other Aerie Pharmaceuticals news, CEO Vicente Anido, Jr. sold 150,000 shares of the company’s stock in a transaction that occurred on Friday, June 8th. The shares were sold at an average price of $62.28, for a total value of $9,342,000.00. Following the transaction, the chief executive officer now owns 176,320 shares in the company, valued at approximately $10,981,209.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Casey C. Kopczynski sold 2,708 shares of the company’s stock in a transaction that occurred on Tuesday, May 29th. The shares were sold at an average price of $50.15, for a total transaction of $135,806.20. Following the completion of the transaction, the insider now owns 194,517 shares in the company, valued at approximately $9,755,027.55. The disclosure for this sale can be found here. In the last quarter, insiders sold 263,708 shares of company stock worth $16,249,556. Company insiders own 10.53% of the company’s stock.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply